↳ Why This Matters
This trial result is significant for early-stage lung cancer patients with specific genetic mutations (RET-positive). Retevmo's demonstrated efficacy could lead to a change in standard treatment protocols, potentially improving long-term outcomes and reducing the need for more aggressive therapies later on.
Key facts
- Retevmo reduced the risk of recurrence or death by 83% in early-stage RET-positive lung cancer patients.
- The findings are from a Phase 3 trial.
- Retevmo is a targeted therapy.
This trial result is significant for early-stage lung cancer patients with specific genetic mutations (RET-positive). Retevmo's demonstrated efficacy could lead to a change in standard treatment protocols, potentially improving long-term outcomes and reducing the need for more aggressive therapies later on.
What Happens Next
01Eli Lilly may seek expanded FDA approval for Retevmo in this patient population.
02Further analysis of long-term survival data from the trial is expected.